Evidence map›Paper›PMID 41896652›Full record

ArticleBritish journal of cancer2026

Comprehensive analysis of FGFR2b and its correlation with essential biomarkers, intratumoral heterogeneity, and survival in advanced gastric cancer.

Yoonjin Kwak, Tae-Yong Kim, Hye Seung Lee, Soo Kyung Nam, Hyeon Jeong Oh, Do-Youn Oh, Seock-Ah Im

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yoonjin KwakDepartment of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
Tae-Yong Kim *Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea. ktyongmd@gmail.com.
Hye Seung Lee *Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea. hye2@snu.ac.kr.ORCID http://orcid.org/0000-0002-1667-7986
Soo Kyung NamCancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
Hyeon Jeong OhDepartment of Pathology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
Do-Youn OhDepartment of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
Seock-Ah ImDepartment of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.ORCID http://orcid.org/0000-0002-5396-6533

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFGFR2b is a new emerging therapeutic target in gastric cancer (GC). This study aimed to examine the clinicopathological characteristics of FGFR2b and its relationship with key biomarkers in locally advanced (LA) and metastatic or unresectable (MU) GC.

methodsFGFR2b immunohistochemistry (IHC) (FPR2-D) positivity was defined as 2 or 3+ in any tumor cells. Additional tests included IHC for CLDN18.2 (43-14 A), HER2, PD-L1 (22C3), microsatellite instability testing, and Epstein-Barr virus ISH.

resultsOf the 1331 patients, 39 (2.9%) and 25 (1.9%) had FGFR2b-positive GC in any % and in ≥10% of tumor cells, respectively. A higher FGFR2b-positivity rate was significantly associated with MU GC and a shorter interval between tumor acquisition and FGFR2b testing. HER2, PD-L1, and CLDN18.2 positivity rates did not differ by FGFR2b status. Intratumoral heterogeneity was observed in 88.0% of FGFR2b-positive resected cases. FGFR2b-positive GC had a trend toward shorter overall survival regardless of clinical factors.

conclusionFGFR2b positivity was higher in MU GC and in GC samples with shorter storage periods. However, no significant association was observed between FGFR2b expression and other key biomarkers or survival outcomes.

Indexed as

Biomarkers, TumorReceptor, Fibroblast Growth Factor, Type 2Stomach NeoplasmsAdultAgedAged, 80 and overB7-H1 AntigenClaudinsErb-b2 Receptor Tyrosine KinasesFemaleHumansImmunohistochemistryMaleMicrosatellite InstabilityMiddle AgedPrognosisB7-H1 AntigenBiomarkers, TumorCD274 protein, humanClaudinsERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesFGFR2 protein, humanReceptor, Fibroblast Growth Factor, Type 2

Identifiers

PMID41896652
PMCPMC13133172

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.